Sort   by:  
 Page size 
UnknownEffectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.

Aim

To evaluates the effectiveness and safety of the first generation, NS3/4A protease inhibitors (PIs) in clinical practice against chronic C virus, especially in patients with advanced fibrosis.

Methods

Prospective study and non-experimental analysis of a multicentre cohort of 38 Sp...
S-EPMC4533049 | biostudies-literature
UnknownRepurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.

Background

World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19).

Methods

We randomly assigned inpa...
S-EPMC7727327 | biostudies-literature
UnknownRemdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.

Background

The Solidarity trial among COVID-19 inpatients has previously reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and interferon (IFN)-β1a were discontinued for futility but randomisation to remdesivir continued. Here, we report ...
S-EPMC9060606 | biostudies-literature
Sort   by:  
 Page size